TYB
Any anons wanna guess who has had their funding in MRSA?
Gates-backed Waltham biotech Arsanis plots $58M IPO
Arsanis lead drug is designed to prevent Staphylococcus aureus pneumonia
After securing funding from GV, the Bill and Melinda Gates Foundation and other private investors, Waltham-based infectious disease biotech Arsanis has announced plans to tap into the public markets.
The 39-employee company said in a federal filing on Friday that it hopes to raise up to $57.5 million in an initial public offering. Shares of Arsanis would trade under the ticker “ASNS.”
So far in 2017, six Massachusetts-based biotechs have gone public. With the filing, Arsanis joins five others that have disclosed plans for IPOs but have yet to hit the Nasdaq.
Friday’s filing comes six months after Arsanis closed a $45 million Series D round led by the Gates Foundation, which has invested significant sums to fight infectious diseases. Other investors in that round included GV, the venture arm of Google parent company Alphabet, and Boston-based Polaris Partners.
Arsanis’ lead drug is designed to prevent Staphylococcus aureus pneumonia — a potentially life-threatening infection — among high-risk patients in intensive care units who are hooked up to ventilators. The drug is currently in a mid-stage study, with data expected in the second half of 2018.
According to Friday’s filing, Arsanis posted a $22.7 million loss in the first nine months of 2017.
The company was launched in 2011 and initially operated out of Vienna, Austria, before opening a U.S. headquarters in Waltham in 2015. In addition to its Waltham headquarters, Arsanis maintains a research facility in Vienna.
https://www.bizjournals.com/boston/news/2017/10/23/gates-backed-waltham-biotech-arsanis-plots-58m-ipo.html